Ratio Therapeutics entered today into an exclusive worldwide license and collaboration agreement with Novartis (NVS) Pharma AG, a subsidiary of Novartis. The collaboration leverages Ratio’s radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments. Ratio will collaborate with Novartis to drive preclinical activities to research and select an SSTR2-targeting development candidate. Novartis will assume responsibility for all remaining development, manufacturing, and commercialization activities.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis says Pluvicto talks in Canada end without agreement
- Biotech Alert: Searches spiking for these stocks today
- Schrodinger price target raised to $28 from $27 at Goldman Sachs
- Reporters tweets about ‘vague whispers’ of bid interest in TG Therapeutics
- Schrodinger price target raised to $28 from $25 at BMO Capital